Source: Healio News
CHICAGO — Daratumumab appeared safe for patients with multiple myeloma who had advanced renal insufficiency, according to study results presented at ASCO Annual Meeting.
“The take-home message from our study is that there was no significant impact of the treatment on renal function at 12 months,” researcher Mateusz Niewinski, BA, BPS, PharmD, pharmacy resident at NYU Langone Health, told Healio. “Compared [with] published data on patients treated with creatinine clearance greater than 30 mL/min, there does not appear to be a detriment to survival or an increase in